Core Insights - The company is experiencing a significant transformation, focusing on field detection technologies and reporting positive adjusted EBITDA in Q4 2025, indicating a successful restructuring of its cost base [1][7]. Business Transformation - Management initiated a shift away from desktop products about a year ago, citing challenges in academic and biopharma markets, which has helped secure the balance sheet and focus on growth areas in public safety, security, and defense [1]. - The company reported an 18% year-over-year growth for 2025, with a cash balance of $113 million and a 57% adjusted gross margin [7]. Product Deployment and Expansion - Over 3,700 devices have been deployed across 700 accounts, with more than 18,000 trained users, emphasizing the value proposition of providing immediate actionable insights [2][6]. - The flagship MX908 handheld mass spectrometry product has been highlighted as a disruptive technology, with over 3,100 units deployed [9]. - Newer products, XplorIR and VipIR, are also gaining traction, with XplorIR achieving 40% year-over-year growth and VipIR generating approximately $3 million in revenue from over 40 shipments in Q4 [10][20]. Market Demand Drivers - The demand for the company's products is driven by escalating threats in public health and security, particularly related to opioids and toxic exposure [14][15]. - Management noted that the threat landscape has expanded, with new substances emerging and an executive order declaring fentanyl a weapon of mass destruction, potentially increasing funding for advanced technologies [14]. 2026 Outlook - The company is guiding for 15% to 20% revenue growth in 2026, with expectations for further margin expansion and a significant reduction in adjusted EBITDA losses [5][17]. - Management aims to achieve cash-flow positivity by 2027-2028, supported by operational improvements and facility consolidations [18][19]. Operational Efficiency - All manufacturing has been consolidated in Danbury, Connecticut, which is expected to enhance margins and support scalability beyond current operations [19]. - The company has not faced significant supply chain issues and is focused on increasing insourcing to capture margins [21]. International and Federal Market Strategy - Approximately 27% of revenue came from international markets, with a notable focus on the Middle East and NATO modernization trends [22]. - The distribution strategy includes direct demand generation in the U.S. and partnerships for international sales, with a focus on simplifying federal contracting through a selected partner [23].

Summary of 908 Devices Conference Call Company Overview - **Company**: 908 Devices (NasdaqGM:MASS) - **Industry**: Life Science Tools and Diagnostics Key Points Industry and Market Dynamics - **Impact of Global Conflicts**: The company noted that global unrest, such as the Ukraine war and tensions in the Middle East, influences demand for their products, particularly in conflict zones where concerns about chemical weapons arise [4][6][12] - **Drivers of Business**: The business is driven by three main factors: 1. Illicit drug crisis and counterfeit pharmaceuticals 2. Toxic industrial chemicals and their impact on frontline workers 3. Increased global unrest leading to heightened demand for chemical detection tools [6][12] Financial Performance - **Fourth Quarter Growth**: The company reported a solid 21% growth in the fourth quarter, attributed to the contribution from RedWave products despite challenges from a government shutdown [32][40] - **Revenue Breakdown**: Approximately 43% of revenues came from state and local customers, with a notable uptick in orders for products like XplorIR and VipIR [36][38] - **International Revenue**: International sales accounted for 27% of total revenues, with expectations for this percentage to increase as global demand rises [14][92] Product Development and Innovation - **Next-Gen Products**: The company is working on a next-generation MX908 device, aiming to reduce size and weight while enhancing user-friendliness. The launch is expected later this year, with a full impact anticipated next year [84][86] - **AVCAD Program**: The AVCAD program is expected to generate $2 million to $3 million in 2026, with potential to ramp up to $10 million annually over the next several years [76][81] - **XplorIR Performance**: The XplorIR product has seen significant growth, with over 150 units installed and a 40% year-over-year growth rate [110][112] Government and Grant Funding - **Grant Funding Opportunities**: The company highlighted the importance of grant funding for state and local customers, with approximately $2 billion available annually for equipment purchases. Recent legislative changes have opened additional funding avenues [52][72] - **DHS Shutdown Impact**: The ongoing DHS shutdown has not had an immediate negative impact on the company’s operations, as many grants are multi-year and already allocated [61][62] Future Outlook - **Growth Projections**: The company anticipates a growth rate of 15%-20% for the upcoming year, with a slower start expected in Q1 due to inventory restocking [40][47] - **Profitability Goals**: The company aims to achieve positive Adjusted EBITDA in the second half of 2026, with a focus on balancing growth and profitability [119][120] Competitive Landscape - **Market Position**: The company believes it has a unique position in the market with its handheld mass spectrometry technology, which is not widely available from competitors [84][110] - **International Expansion**: There are plans to increase international sales efforts, particularly in Europe and APAC, with a goal of significantly raising the percentage of international revenue [96][100] Financial Management - **Cost Management**: The company is focused on improving gross margins through insourcing and operational efficiencies, with expectations for margins to reach the high fifties percentage range [125][126] - **Recurring Revenue Growth**: Recurring revenue was up 22% year-over-year, making up about 35% of total revenues, with plans to increase this further [129][132] Conclusion - **Strategic Focus**: 908 Devices is strategically positioned to capitalize on growing market demands driven by global unrest and increased funding for safety and detection technologies. The company is focused on innovation, expanding its product offerings, and enhancing its international presence while maintaining a balanced approach to profitability and growth.

Summary of 908 Devices FY Conference Call Company Overview - **Company**: 908 Devices (NasdaqGM:MASS) - **Industry**: Handheld chemical detection tools for health, safety, and defense technology applications Key Financial Highlights - **Q4 2025 Revenue Growth**: Achieved approximately 18% year-over-year growth in top-line revenue [4] - **Adjusted EBITDA**: Reached a positive adjusted EBITDA of $0.7 million in Q4 2025, marking a significant milestone in the company's transformation [5] - **Revenue Contribution**: Exceeded $56 million in total revenue for the full year 2025 [14] Market Focus and Drivers - **End Markets**: Focused on handheld, deployable devices serving health, safety, and defense technology sectors [12] - **Key Demand Drivers**: - **Illicit Drug Crisis**: Strong demand driven by the ongoing crisis, particularly concerning substances like fentanyl and cocaine [12] - **Toxic Industrial Chemicals**: Increased need for monitoring carcinogens and exposure for first responders [12] - **Global Defense Concerns**: Rising unrest globally, including conflicts in Ukraine and Iran, driving demand for defense-related products [12][13] Product Performance - **VipIR**: Launched in Q3, contributed over $3 million in revenue in Q4 with more than 40 devices sold [14] - **XplorIR**: Introduced a quant model, shipped over 150 devices, and gained traction across various customer segments [15] - **AVCAD**: Expected to contribute $2 million-$3 million in 2026, with potential for $10 million annually at full production [39][45] - **MX908**: Anticipated growth driven by opioid funding and international events [15] Operational Efficiency and Margins - **Adjusted Gross Margin**: Currently at 56.7%, with a target of at least 100 basis points improvement [36] - **Cost Structure**: Improved through divestment of the desktop business and insourcing capabilities [5][36] Strategic Initiatives - **TeamLeader Software**: Aims to enhance connectivity and data sharing across devices, currently in a free version with plans for a paid model [64][66] - **OEM Partnerships**: Expanding access to platforms through partnerships without incurring full sales and marketing costs [50] Future Outlook - **Revenue Guidance for 2026**: Projected growth of 15%-20% driven by product demand and market expansion [14] - **Defense Spending**: Anticipated increase in defense budgets across NATO countries, expected to benefit the company [23][25] - **Product Replacement Cycle**: Strong potential for growth in FTIR device replacements, with a significant portion of placements last year being FTIR-based [56] Conclusion 908 Devices is positioned for growth through its focus on innovative handheld detection tools, driven by strong market demand in health, safety, and defense sectors. The company is leveraging operational efficiencies and strategic partnerships to enhance its product offerings and expand its market reach.

Core Insights - The company reported a fourth-quarter revenue of $17.4 million from continuing operations, reflecting a 21% year-over-year increase, primarily driven by strong demand for the XplorIR gas identification device and the new VipIR product [4][8] - The total number of devices shipped in the fourth quarter was 224, increasing the installed base to 3,736 [1][8] - Management provided guidance for 2026 revenue between $64.5 million and $67.5 million, indicating a growth rate of 15% to 20% compared to 2025 [6][17] Financial Performance - Handheld product and service revenue reached $16.0 million in the fourth quarter, up 18%, largely due to FTIR products [2] - The company achieved a positive adjusted EBITDA of $0.7 million, a significant improvement from a $4.0 million loss in the previous year [7][9] - Gross margin improved to 53%, with an adjusted gross margin of 57%, up approximately 530 basis points year-over-year [9] Operational Highlights - The company ended 2025 with $113 million in cash and marketable securities, with no outstanding debt [6][14] - Operating expenses decreased to $6.1 million in the fourth quarter, down from $23.4 million in the prior year, primarily due to the absence of non-cash charges [10] - The state and local sales channel revenue grew by 38% to approximately $24 million, representing 43% of total 2025 revenue [13] Product Developments - The VipIR product, launched in July 2025, combines FTIR and Raman spectroscopy with proprietary Smart Spectral Processing [18] - The next-generation MX platform is on track for a commercial launch later in 2026 [18] - The company consolidated U.S. federal contracting partners to improve procurement efficiency [15] Market Expansion - International revenue accounted for 27% of total revenue in 2025, up from 25% in 2024, with increased defense budgets among NATO countries [16] - The company is shipping chemical detection devices to various countries, including Poland and Ukraine [16] - Management emphasized the focus on scaling proven platforms and strengthening revenue durability through recurring revenue [20]

Core Insights - The company reported a strong financial performance for 2025, achieving $56.2 million in revenue, which reflects an 18% year-over-year growth, driven by the adoption of its innovative devices in health, safety, and defense applications [2][22] - The Explorer device has been a key growth driver, with over 150 units sold and a year-over-year growth of more than 40%, highlighting its demand among emergency response teams [5][49] - The company has consolidated its contracting partners to improve procurement efficiency and predictability in its U.S. federal government business, which is expected to enhance revenue visibility [6][34] Financial Performance - For Q4 2025, the company reported $17.4 million in revenue, marking a 21% increase from the previous year, with a positive adjusted EBITDA of $700,000 compared to a loss of $4 million in the prior year [4][21] - The full-year gross profit was $28.4 million, with a gross margin of 51%, while adjusted gross profit reached $31.9 million, reflecting a 57% margin [23][19] - The company ended 2025 with $113 million in cash and no debt, providing a solid financial foundation for future growth [12][25] Product Development and Market Expansion - The launch of the Viper device in July 2025 has been well-received, generating over $3 million in revenue from more than 40 units shipped in Q4 [10][8] - The company is focusing on expanding its international presence, with 27% of revenues coming from outside the U.S., an increase from 25% in 2024, particularly in NATO countries [7][26] - The company plans to continue modernizing legacy detection equipment and expanding its product portfolio to drive future growth [13][64] Strategic Focus Areas - The company has identified three strategic focus areas for 2026: scaling proven platforms, extending platform leadership, and strengthening revenue durability through recurring revenue opportunities [12][14] - The company aims to achieve revenue growth of 15% to 20% in 2026, with expectations for handheld product and service revenue to grow by 13% to 17% [26][27] - The operational improvements and cost management strategies implemented in 2025 are expected to continue benefiting the company in the coming years [11][29]

Financial Data and Key Metrics Changes - The company achieved $17.4 million in revenue from continuing operations in Q4 2025, representing a robust 21% year-over-year growth from $14.3 million in Q4 2024 [4][17] - For the full year 2025, revenue was $56.2 million, an 18% increase from $47.7 million in 2024, driven primarily by FTIR products [5][23] - Adjusted EBITDA for Q4 2025 was positive at $0.7 million, a significant improvement from a loss of $4 million in the prior year [5][22] - The company ended 2025 with $113 million in cash, with no debt outstanding, indicating a strong financial position [14][26] Business Line Data and Key Metrics Changes - Handheld product and service revenue was $16 million in Q4 2025, up 18% from $13.6 million in Q4 2024, driven by FTIR products [17] - Recurring revenue, which includes consumables, accessories, software, and service revenue, represented 32% of total revenues in Q4 2025, amounting to $5.5 million, an 11% increase year-over-year [19] - The XplorIR device achieved over 40% year-over-year growth, with more than 150 units delivered in its first full year of commercial sales [8][52] Market Data and Key Metrics Changes - 27% of revenues in 2025 came from international markets, an increase from 25% in 2024, with significant sales growth in NATO countries [10] - The company noted strong demand for its products in Europe, particularly due to increased defense budgets related to the ongoing war in Ukraine [10] Company Strategy and Development Direction - The company aims to scale proven platforms, extend platform leadership, and strengthen revenue durability as part of its strategic focus for 2026 [14][15] - The introduction of the VipIR device is expected to drive growth, with the company anticipating a full year of impact in 2026 [15][52] - The consolidation of contracting partners to one for U.S. federal government business is intended to improve procurement efficiency and forecasting accuracy [9][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capitalize on growth opportunities driven by increased funding for public safety and defense [30] - The company expects revenue growth of 15%-20% in 2026, with guidance reflecting the anticipated impact of new products and market conditions [26][27] - Management highlighted the importance of their mission to protect frontline responders, emphasizing the societal value of their products [31] Other Important Information - The company reported a significant reduction in operating expenses for Q4 2025, totaling $6.1 million compared to $23.4 million in the prior year, largely due to non-cash items in 2024 [21] - The adjusted gross margin for the full year 2025 was 57%, an increase from 56% in 2024, driven by improved service and contract gross margins [25] Q&A Session Summary Question: Relationship with Mountain Horse - The company consolidated contracting partners to improve procurement efficiency and forecasting visibility, leveraging Mountain Horse's strong procurement relationships [33][36] Question: Next Gen MX908 Platform - The next-gen MX908 platform is on schedule for commercial launch in 2026, with expectations for significant demand due to its differentiated capabilities [41][42] Question: Growth Drivers for 2026 - Key growth drivers include the full-year impact of VipIR, continued demand for XplorIR, and increased defense spending due to global concerns [48][52] Question: Impact of Current Conflicts - Management does not foresee immediate disruptions from current conflicts but acknowledges potential increases in demand for their products [65][66] Question: Adjusted EBITDA Expectations - The company aims to cut its adjusted EBITDA loss in half for 2026, targeting low to mid-single-digit millions, while maintaining growth opportunities [59][60]

Financial Data and Key Metrics Changes - The company achieved $17.4 million in revenue from continuing operations in Q4 2025, representing a robust 21% year-over-year growth from $14.3 million in Q4 2024 [4][17] - For the full year 2025, total revenue was $56.2 million, an 18% increase from $47.7 million in 2024 [23] - Adjusted EBITDA for Q4 2025 was positive $0.7 million, a significant improvement from a loss of $4 million in the prior year [5][22] - The company ended 2025 with $113 million in cash and no debt outstanding, strengthening its financial position [14][26] Business Line Data and Key Metrics Changes - Handheld product and service revenue was $16 million in Q4 2025, up 18% from $13.6 million in Q4 2024, driven by FTIR products [17] - Recurring revenue, which includes consumables, accessories, software, and service revenue, represented 32% of total revenues in Q4 2025, amounting to $5.5 million, an 11% increase year-over-year [19] - The XplorIR device achieved over 40% year-over-year growth, with more than 150 units delivered in its first full year of commercial sales [8][51] Market Data and Key Metrics Changes - 27% of revenues in 2025 came from outside the United States, an increase from 25% in 2024, with significant sales growth along NATO's eastern flank [10] - The company noted strong demand for its products in Europe, particularly due to increased defense budgets among NATO countries [9] Company Strategy and Development Direction - The company aims to scale proven platforms, extend platform leadership, and strengthen revenue durability in 2026 [15] - The focus is on modernizing legacy detection equipment, particularly FTIR, and driving growth through new product introductions like VipIR [15][44] - The company is consolidating contracting partners to improve procurement efficiency and predictability in its U.S. federal government business [9][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capitalize on significant growth opportunities driven by increased funding for public safety and defense [30] - The company anticipates revenue growth of 15%-20% in 2026, with expectations for handheld product and service revenue to grow 13%-17% year-over-year [26][27] - Management highlighted the importance of their mission to protect frontline responders, which aligns with their technology leadership and operational excellence [31] Other Important Information - The company reported a significant reduction in total operating expenses for Q4 2025 to $6.1 million, down from $23.4 million in the prior year, largely due to non-cash items in 2024 [21] - The company is focused on maintaining a disciplined cost management approach while investing in growth opportunities [14][29] Q&A Session Summary Question: Relationship with Mountain Horse - Management explained the decision to consolidate contracting partners to improve procurement efficiency and visibility, emphasizing the unique capabilities of Mountain Horse in supporting government contracts [33][36] Question: Next Gen MX908 Platform - Management confirmed that the next-gen MX908 platform is on schedule for commercial launch, with expectations for significant demand due to its differentiated capabilities [40][41] Question: Growth Drivers for 2026 - Management discussed various growth drivers, including the impact of the VipIR product and increased defense spending, while also addressing potential challenges from ongoing conflicts [47][48] Question: Impact of Middle East Conflict - Management indicated that while conflicts can create uncertainty, they do not currently see a significant impact on their operations or demand [64][66] Question: Commercial Efforts and OpEx - Management outlined plans to increase commercial efforts, particularly in state and local markets, while also investing in international sales capabilities [67][69]

Financial Data and Key Metrics Changes - The company achieved $17.4 million in revenue for Q4 2025, representing a 21% year-over-year growth from $14.3 million in Q4 2024 [16] - For the full year 2025, revenue was $56.2 million, an 18% increase from $47.7 million in 2024 [21] - Adjusted EBITDA for Q4 2025 was $0.7 million, a significant improvement from a loss of $4 million in the prior year [20] - The company ended 2025 with $113 million in cash and no debt outstanding [24] Business Line Data and Key Metrics Changes - Handheld product and service revenue for Q4 2025 was $16 million, up 18% from $13.6 million in Q4 2024, driven by FTIR products [16] - Recurring revenue represented 32% of total revenues in Q4 2025, amounting to $5.5 million, an 11% increase year-over-year [18] - The XplorIR device achieved over 40% year-over-year growth, with more than 150 units delivered in its first full year of sales [7][49] Market Data and Key Metrics Changes - 27% of revenues in 2025 came from outside the U.S., up from 25% in 2024, with significant sales growth in NATO countries [9] - The state and local sales channel grew 38% to approximately $24 million, representing 43% of total revenues for 2025 [21] Company Strategy and Development Direction - The company aims to scale proven platforms, extend platform leadership, and strengthen revenue durability in 2026 [13][14] - Focus on increasing adoption of devices to address global threats to public health and safety, particularly through the XplorIR and VipIR products [6][10] - The company is consolidating contracting partners to improve procurement efficiency and predictability in U.S. federal government business [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capitalize on growth opportunities driven by increased funding for public safety and defense [28] - The company anticipates revenue growth of 15%-20% in 2026, with expectations for continued demand for its products amid global defense spending increases [24][25] - Management highlighted a strong late-stage pipeline and favorable U.S. policy decisions as key factors for sustained growth [28] Other Important Information - The company has made significant operational improvements, including manufacturing consolidation and cost management, leading to a right-sized cost structure [12] - The introduction of the VipIR device is expected to have a full-year impact in 2026, contributing to revenue growth [10] Q&A Session Summary Question: What is the rationale behind the partnership with Mountain Horse? - The partnership aims to drive procurement efficiency and improve forecasting visibility by consolidating from four partners to one, enhancing the ability to deliver fully configured solutions to the U.S. government [32][34] Question: How will the new MX908 platform be adopted? - The next-gen MX908 platform is on schedule for commercial launch, with expectations for demand from both existing and new customers due to its enhanced capabilities [39][41] Question: What factors will influence revenue growth in 2026? - Key growth drivers include the full-year impact of VipIR, continued demand for XplorIR, and increased funding for defense and public safety initiatives [45][49]

Summary of 908 Devices FY Conference Call Company Overview - **Company**: 908 Devices (NasdaqGM:MASS) - **Focus**: Transitioned from a broad instrumentation provider to a company focused on handheld chemical detection for public health, safety, and defense through a transformation called "908 2.0" [2][6] Key Points Transformation and Business Focus - The transformation is complete, with a focus on growth markets, specifically handheld chemical detection [3] - Divested the desktop business to sharpen focus on handheld markets, which are seeing increased demand due to macro trends like the opioid crisis and defense modernization [3][4] - The company aims for 13%-17% growth this year, accelerating to over 20% next year on the product side [3] Financial Performance - Year-to-date revenue growth of 16% driven by new product launches [10] - Gross margins improved to 56% year-to-date, reaching 58% in Q3 due to operational streamlining and manufacturing consolidation [11] - Adjusted EBITDA loss improved by 32% year-over-year and 53% quarter-over-quarter [4] - Projected revenue for the full year is between $54 million and $56 million, with a goal of achieving positive adjusted EBITDA in Q4 [12] Product Development and Market Strategy - Expanded product portfolio from one handheld device to five, with more in development [5][9] - New handheld analyzer, Viper, launched in Q3, combining FTIR and Raman technologies for enhanced chemical identification [17][20] - Explorer device has seen strong sales, with a 30% quarter-over-quarter growth and significant adoption among first responders [23][24] Growth Catalysts for 2026 - Key growth drivers identified as equipment modernization, the NextGen MX908 launch, and the DOD AFCAD program [32][33] - The company expects to leverage a legacy base of over 15,000 products for upgrades, with a focus on innovative solutions [33] - Anticipated revenue from the AFCAD program could exceed $10 million when fully ramped [36] Market Opportunities - Strong traction in state and local government markets, driven by funding opportunities and the need for advanced chemical detection due to the opioid crisis [30][31] - International expansion opportunities identified, particularly in the Middle East and potential growth in APAC [11][30] Recurring Revenue Strategy - Approximately one-third of revenue comes from service and support contracts, with plans to enhance connected services through the Team Leader software application [25][26][27] Cash Position and Investment Strategy - Strong cash position of $112 million with no debt, allowing flexibility for organic and potential inorganic investments [37][38] Additional Insights - The company is focused on maintaining a simplified operational model while pursuing high-impact markets [6] - The transformation is seen as a pivotal shift, positioning the company for long-term growth and profitability [2][6]

Summary of 908 Devices Conference Call Company Overview - **Company**: 908 Devices (NasdaqGM:MASS) - **Industry**: Life Sciences and Diagnostics Key Financial Highlights - **Q3 Revenue**: $14 million, exceeding consensus of $13.5 million [3][4] - **Guidance**: Maintained revenue guidance of $54 million to $56 million for Q4 [25] - **Cash Position**: Ended the quarter with $112 million in cash [5] Business Transformation - **Acquisition**: Acquired RedWave, enhancing handheld product portfolio from 1 to 5 products [5][6] - **Divestiture**: Sold PAT business to Repligen, generating approximately $70 million [5] - **Cost Structure**: Consolidated manufacturing to Danbury, Connecticut, leading to a lower cost footprint [6] Product Development and Market Focus - **Product Launches**: Continued launch of Viper product and Explorer, with record performance [4][8] - **Market Segments**: Focus on drug detection (e.g., fentanyl crisis) and toxic materials [6][30] - **Government Partnerships**: Collaboration with Smith's Detection for the Avcad program targeting military applications [11][12] Revenue Streams and Diversification - **Revenue Sources**: 47% from state and local channels, 25% from international channels [28] - **Fentanyl Detection**: Majority of revenues driven by fentanyl and drug detection capabilities [36][37] Challenges and Risks - **Government Shutdown Impact**: Approximately $4 million in revenue tied up due to government shutdown, affecting Q4 revenue recognition [24][25] - **Export Licensing Delays**: $1 million to $3 million in international orders pending export license approval [26] Future Growth Catalysts - **Next-Gen Products**: Anticipated launch of next-generation MX908, expected to enhance market position [40][42] - **Enterprise Accounts**: Potential for enterprise-level deals with Viper and Explorer products [55][56] - **Long-Term Growth**: Projected 20% product growth in 2026, with opportunities for further expansion in 2027 and beyond [75] Operational Insights - **Production Capacity**: Confident in production capabilities to meet demand, with plans to ramp up labor as needed [19][20] - **Partnerships**: Emphasizing strategic partnerships to enhance market reach and product integration [70][71] Profitability Outlook - **Adjusted EBITDA**: Expected positive adjusted EBITDA in Q4, with a target of $16 million [73] - **Sustained Profitability**: Anticipated crossover into consistent profitability in the future, though 2026 may not be the year for sustained positive results [74] Conclusion - **Overall Sentiment**: Positive outlook on business transformation, product innovation, and market opportunities, despite short-term challenges related to government operations and export licensing delays [76][78]